In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: Results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 1, 2016, Pages 162-169

  Karlowsky, James A ^a   Biedenbach, Douglas J ^a   Bouchillon, Samuel K ^a   Iaconis, Joseph P ^b   Reiszner, Edina ^b   Sahm, Daniel F ^a  

^a International Health Management Associates   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CLINDAMYCIN; DAPTOMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; ESCHERICHIA COLI; EUROPE; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; PROTEUS MIRABILIS; RUSSIAN FEDERATION; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES; TURKEY (REPUBLIC); BACTERIUM; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HUMAN; ISOLATION AND PURIFICATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREVALENCE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIA; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; EUROPE; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84960082251     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv311     Document Type: Article

References (24)

1. Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59: e10-52.
2. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 Suppl 3: iii35-44.
3. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
4. Jeng A, Beheshti M, Li J et al. The role of b-hemolytic streptococci in causing diffuse, nonculturable cellulitis. Medicine 2010; 89: 217-26.
5. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In: Bennett JE, Dolin R, Blaser MJ, eds. Principles and Practices of Infectious Diseases. Philadelphia: Elsevier Saunders, 2014; 1194-215.
6. Moellering RC Jr. The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother 2010; 65 Suppl 4: iv3-8.
7. Corey GR, Wilcox MH, Talbot GH. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv41-51.
8. Wilcox MH, Corey GR, Talbot GH. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv53-65.
9. Teflaro, Package Insert. Forest Laboratories, December 2013. http:// www.accessdata.fda.gov/drugsatfda_docs/label/2010/200327s000lbl.pdf.
10. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
12. EUCAST. Breakpoint Tables for Interpretation ofMICs and Zone Diameters, Version 4.0. January 2014. http://www.eucast.org/clinical_breakpoints/.
13. Tygacil, Package Insert. Pfizer, Revised January 2014. http://www. accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf.
14. Alm RA, McLaughlin RE, Kos VN et al. Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother 2014; 69: 2065-75.
15. Farrell DJ, Flamm RK, Sader HS et al. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). Int J Antimicrob Agents 2013; 41: 337-42.
16. Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010; 65 Suppl 4: iv17-31.
17. Flamm RK, Farrell DJ, Sader HS et al. Antimicrobial activity of ceftaroline combined with avibactamtested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). Diagn Microbiol Infect Dis 2014; 78: 449-56.
18. Pfaller MA, Flamm RK, Sader HS et al. Ceftaroline activity against bacterial organisms isolated fromacute bacterial skin and skin structure infections in United States medical centers (2009-2011). Diagn Microbiol Infect Dis 2014; 78: 422-8.
19. Ge Y, Biek D, Talbot GH et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-407.
20. MacGowan AP, Noel AR, Tomaselli S et al. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacodynamics model of infection. Antimicrob Agents Chemother 2013; 57: 2451-6.
21. Long SW, Olsen RJ, Mehta SC et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2014; 58: 6668-74.
22. Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-11.
23. Saravolatz SN, Martin H, Pawlak J et al. Ceftaroline-heteroresistant Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58: 3133-6.
24. Fernandez R, Paz LI, Rosato RR et al. Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance. Antimicrob Agents Chemother 2014; 58: 5736-46.